Microba Launches Next Generation Healthcare Testing
28.2.2023 12:44:00 EET | Business Wire | Press release
Microba Life Sciences Limited (ASX: MAP) (“Microba”), a precision microbiome company, is pleased to announce that it’s next generation testing product range, MetaXplore™ has been launched to healthcare professionals in Australia under a new brand, Co-Biome™. This delivers on the new healthcare product launch milestone prefaced in the FY22 Annual Report and updated in quarterly reports following the closed beta release in June 2022.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230228005713/en/
MetaXplore™ GI Plus can help you explore the impact your patients’ gut microbiome may be having on their health. MetaXplore™ GI Plus translates diagnostic gastrointestinal markers and targeted pathogen, protist and parasite panels1 alongside metagenomic-driven gut microbiome insights2 for over 28,000* microbial species and their function. (Photo: Business Wire)
Microba’s Chief Executive Officer, Dr Luke Reid said, “The new MetaXplore™ test range delivers an important advancement in how microbiome test information can be applied in a healthcare setting. We continue to make progress at the forefront of this field to advance the application of microbiome testing in a healthcare setting towards a future where it can be routine in health and disease management, much like a blood test is today.”
The new MetaXplore™ range provides diagnostic gastrointestinal health testing together with metagenomic-driven gut microbiome analysis to deliver comprehensive gastrointestinal testing solutions for Healthcare Professionals. The MetaXplore™ test range has been developed together with healthcare professionals and brought to market under a new brand called Co-Biome™.
The range consists of 3 products: MetaXplore™, MetaXplore™ GI and MetaXplore™ GI Plus. Key features include:
- Easy to interpret report format designed specifically for healthcare professionals to support efficient patient consultation
- Scientifically graded clinical insights using National Health and Medical Research Council guidelines
- Diagnostic and investigative gastrointestinal health markers (faecal calprotectin, faecal occult blood, lactoferrin, pancreatic elastase, secretory IgA, Zonulin, Fecal pH)
- Diagnostic pathogen and parasite detection (E.coli pathotypes, C.difficile pathotypes, Campylobacter spp., Yersinia enterocolitica, Vibrio spp., Aeromonas spp., Salmonella spp., Giardia lamblia, Entamoeba histolytica, Cryptosporidium spp., Dientamoeba fragilis, Cyclospora cayetanensis.)
- Complete microbiome profiling (Microbial diversity, richness and profiling of over 28,000+ microbial species including bacteria, fungi, parasite and archaea detection, together with parasite detection of Blastocystis subtypes 1-9 and other eukaryotes)
- Microbiome production and consumption of metabolites (Butyrate, acetate, propionate, 3-indolepropionic acid (IPA), hexa-acylated, lipopolysaccharides (hexa-LPS), trimethylamine (TMA), hydrogen sulphide, branched-chain amino acids (BCAA), B.fragilis toxin, methane, beta-glucuronidase, Mucin, oxalate)
A core component of Microba’s strategy is to leverage the Company’s world-leading technology and capability to advance the clinical application of microbiome testing to become embedded as a routine part of health and disease management. The MetaXplore™ test range through Co-Biome™ represents an important step forward in that strategy by breaking new ground in the application of microbiome testing in healthcare.
Microba’s Chief Scientific Officer, Assoc Prof. Lutz Krause said, “These new tests integrate traditional gastrointestinal pathology tools with Microba’s next generation microbiome testing technology and the latest global research to significantly advance the utility of microbiome testing in a healthcare setting. This test range is expected to significantly expand the total addressable market for Microba’s testing products.”
The test range through Co-Biome™ can be accessed in Australia through a healthcare professional, and following the launch, it is expected to then be rolled out through Microba’s growing international distribution partner network.
About Microba Life Sciences Limited
Microba Life Sciences is a precision microbiome company driven to improve human health. With world-leading technology for measuring the human gut microbiome, Microba is driving the discovery and development of novel therapeutics for major chronic diseases and delivering gut microbiome testing services globally to researchers, clinicians, and consumers. Through partnerships with leading organisations, Microba is powering the discovery of new relationships between the microbiome, health and disease for the development of new health solutions.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230228005713/en/
Contact information
Simon Hinsley simon@nwrcommunications.com.au
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Xsolla and the Dubai Films and Games Commission Create a Strategic Partnership to Connect Dubai-Based Developers to Global Markets21.5.2026 06:16:00 EEST | Press release
Xsolla, a leading global video game commerce company, and the Dubai Games Commissioner, in coordination with the Dubai Films and Games Commission, announced a multi-year strategic partnership to accelerate the development of the video game industry and expand commercial access for developers operating across the Middle East and North Africa. The announcement was made at GamesBeat Summit 2026 in Los Angeles, California. The partnership will unite Xsolla's global commerce infrastructure, including direct-to-consumer storefronts, intelligent payments across 1,000+ payment methods in 200+ geographies, and player engagement tools, with DFGC's mandate to establish Dubai as a world-class destination for video game development and publishing. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260520329315/en/ Xsolla and the DFGC partner to connect developers to global markets. Together, the organizations will launch a joint studio accel
Marquee Brands Enters Strategic Partnership With DAMAC Group for a Majority Interest in Roberto Cavalli20.5.2026 21:30:00 EEST | Press release
Marquee Brands, the premier global brand management company and leading brand accelerator, today announced a definitive agreement for a majority interest in Roberto Cavalli, through a strategic partnership with DAMAC Group, the leading Dubai-based global conglomerate and luxury real estate developer. The transaction is expected to close in the second quarter of 2026, after which DAMAC Group will remain a significant shareholder. Founded in Florence in 1970, Roberto Cavalli the iconic luxury house celebrated for its avant-garde design and distinct Italian craftsmanship joins Marquee Brands’ portfolio of timeless global brands, including Martha Stewart, Laura Ashley, Sur La Table, BCBGMAXAZRIA and Stance. The addition of Roberto Cavalli further strengthens Marquee Brands’ position as a leader in the luxury and lifestyle sectors, bringing total portfolio-wide retail sales to approximately US$5 billion. This press release features multimedia. View the full release here: https://www.busines
Variational Secures ~$50M to Bring Liquidity from Traditional Markets To Crypto20.5.2026 20:07:00 EEST | Press release
Variational, a protocol for on-chain derivatives trading, has announced a ~$50M Series A raise led by Dragonfly with support from Bain Capital Crypto, Coinbase Ventures, and other strategic investors. The funding coincides with the launch of the protocol’s first Real-World Asset (RWA) markets. This initial rollout allows traders to access perpetuals on select commodities alongside their crypto portfolio, laying the groundwork for Variational to route liquidity directly from traditional markets in the coming months. While the broader crypto industry is attempting to bootstrap RWA liquidity from scratch on isolated Central Limit Order Books (CLOBs), Variational introduces a fundamentally different architecture. Instead of starting new order books from scratch for each new market, Variational aggregates and routes liquidity from both existing traditional and on-chain markets. By solving this "cold start" problem, Variational will allow traders to access a massive menu of global assets, fr
EIG’s MidOcean Energy Announces $120m Investment from The Arab Energy Fund as Part of Equity Raise20.5.2026 18:29:00 EEST | Press release
MidOcean Energy (“MidOcean” or the “Company”), a liquefied natural gas (LNG) company formed and managed by EIG, today announced a $120 million equity investment from The Arab Energy Fund (‘’TAEF’’), a leading multilateral impact financial institution, as part of its current equity capital raise. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260520063539/en/ TAEF’s investment further strengthens MidOcean’s high-quality investor base and underscores continued strong interest in the Company’s strategy to build a diversified, resilient and long-life global LNG business. There is significant further momentum from additional investors currently in documentation, and MidOcean will continue to raise capital, with a cumulative target of up to $2 billion from new investors. R. Blair Thomas, MidOcean Chairman and EIG CEO, said: “We are delighted to welcome The Arab Energy Fund as a shareholder in MidOcean. Their significant expertise
TestMu AI Expands Real Device Testing With Multi-Language Playwright Support and Advanced Audio Testing for iOS20.5.2026 18:26:00 EEST | Press release
TestMu AI (formerly LambdaTest), the world’s first full-stack Agentic AI Quality Engineering platform, today announced two major enhancements to its Real Device Cloud: expanded support for Playwright automation across multiple programming languages and the introduction of Audio Injection and Live Audio Input capabilities for real iOS devices. These updates address a growing need for testing modern applications that are not only cross-platform but also increasingly multimodal, involving voice, audio, and real-time user interactions. With the latest release, TestMu AI now supports running Playwright tests on real devices using Java, Python, and C# in addition to existing capabilities. This allows enterprise teams to adopt Playwright within their preferred language ecosystems without being restricted to JavaScript-based workflows. As Playwright adoption continues to grow across engineering teams, this enhancement enables seamless integration of real device testing into existing automation
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom